Om

Nuvation Bio Inc. is a commercial-stage biopharmaceutical company specializing in oncology therapies. The company focuses on cancers with clear molecular drivers and high unmet medical need, emphasizing precision oncology for difficult-to-treat solid tumors. Its current portfolio centers on targeted small-molecule drugs, including taletrectinib, a next-generation ROS1 inhibitor marketed for ROS1-positive non-small cell lung cancer, and safusidenib, a brain-penetrant inhibitor of mutant IDH1 designed for IDH1-driven tumors. Nuvation Bio also advances an innovative drug-drug conjugate program, using proprietary small-molecule constructs to deliver dual therapeutic modalities in a single agent. Operating today as a development-and-commercialization coordinator rather than a large-scale manufacturer, the company creates value by selecting, developing, regulating, and commercializing specialized oncology medicines. Founded in 2018 and headquartered in New York, with additional offices in San Francisco, Boston, and Shanghai, Nuvation Bio plays a growing role in the global market for targeted cancer therapies.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I NUVATION BIO MED ENDAVU: Køb Nuvation Bio ($1E30) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Nuvation Bio, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.